Cyclophosphamide as a first-line therapy in LGL leukemia

被引：80

作者：

Moignet, A. ^{[1
]}

Hasanali, Z. ^{[2
]}

Zambello, R. ^{[3
]}

Pavan, L. ^{[3
]}

Bareau, B. ^{[4
]}

Tournilhac, O. ^{[5
]}

Roussel, M. ^{[6
]}

Fest, T. ^{[6
,8
]}

Awwad, A. ^{[2
]}

Baab, K. ^{[2
]}

Semenzato, G. ^{[3
]}

Houot, R. ^{[1
,7
,8
]}

Loughran, T. P., Jr. ^{[2
]}

Lamy, T. ^{[1
,7
,8
]}

机构：

[1] Rennes Univ Hosp, Dept Clin Hematol, Rennes, France

[2] Penn State Coll Med, Penn State Hershey Canc Inst, Hershey, PA USA

[3] Univ Padua, Sch Med, Dept Med, Hematol & Clin Immunol Branch, Padua, Italy

[4] Clin Cesson Sevigne Rennes, Rennes, France

[5] Hop Estaing, Dept Clin Hematol, Clermont Ferrand, France

[6] Rennes Univ Hosp, Hematol Immunol & Cell Therapy Dept, Rennes, France

[7] INSERM, CIC 0203, F-75654 Paris 13, France

[8] Univ Rennes 1, Rennes, France

来源：

LEUKEMIA | 2014年 / 28卷 / 05期

关键词：

GRANULAR LYMPHOCYTE LEUKEMIA; RED-CELL APLASIA; STAT3; MUTATIONS; LYMPHOPROLIFERATIVE DISEASE; COHORT;

D O I：

10.1038/leu.2013.359

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1134 / 1136

页数：4

共 50 条

[1] Cyclophosphamide as a first-line therapy in LGL leukemia
A Moignet
Z Hasanali
R Zambello
L Pavan
B Bareau
O Tournilhac
M Roussel
T Fest
A Awwad
K Baab
G Semenzato
R Houot
T P Loughran
T Lamy
Leukemia, 2014, 28 : 1134 - 1136
[2] CYTOXAN AS FIRST-LINE THERAPY IN LGL LEUKEMIA : REPORT OF A SERIES OF 21 PATIENTS
Moignet, A.
Zambello, R.
Pavan, L.
Bareau, B.
Tournilhac, O.
Roussel, M.
Houot, R.
Lamy, T.
HAEMATOLOGICA, 2012, 97 : 299 - 300
[3] First-Line Therapy for Chronic Lymphocytic Leukemia
Cherng, Hua-Jay J.
Jain, Nitin
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2021, 35 (04) : 725 - 738
[4] Comparison the Survival Rate of Fludarabine, Chlorambucil and Cyclophosphamide as First-Line Therapy in Patients with Chronic Lymphocytic Leukemia
Sedaghat, Sadegh
Montazeri, Maryam
Rashidi, Negin
Montazeri, Mahdi
Montazeri, Mohammad
ANNALS OF MEDICAL AND HEALTH SCIENCES RESEARCH, 2018, 8 (01) : 99 - 104
[5] Outcome of First Salvage Therapy in Patients With Chronic Lymphocytic Leukemia Relapsing After First-line Fludarabine, Cyclophosphamide, and Rituximab
Badoux, Xavier
Tam, Constantine
Lerner, Susan
Wierda, William
Keating, Michael J.
CLINICAL LYMPHOMA & MYELOMA, 2009, 9 (06): : E39 - E40
[6] First-line therapy of advanced chronic lymphocytic leukemia
Wilhelm, M
Tony, HP
RueckleLanz, H
Wilms, K
LEUKEMIA, 1997, 11 : S14 - S18
[7] Choosing first-line therapy for chronic lymphocytic leukemia
Jaglowski, Samantha
Jones, Jeffrey A.
EXPERT REVIEW OF ANTICANCER THERAPY, 2011, 11 (09) : 1379 - 1390
[8] Nilotinib as first-line therapy for chronic myeloid leukemia
Vaid, A.
INDIAN JOURNAL OF CANCER, 2011, 48 (04) : 438 - 445
[9] Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia
Eichhorst, BF
Busch, R
Hopfinger, G
Pasold, R
Hensel, M
Steinbrecher, C
Siehl, S
Jäger, U
Bergmann, M
Stilgenbauer, S
Schweighofer, C
Wendtner, CM
Döhner, H
Brittinger, G
Emmerich, B
Hallek, M
BLOOD, 2006, 107 (03) : 885 - 891
[10] Optimizing First-Line Therapy for Patients With Chronic Myeloid Leukemia
Fava, Carmen
Cortes, Jorge
SEMINARS IN HEMATOLOGY, 2009, 46 (02) : S5 - S10

← 1 2 3 4 5 →